Panacea Biotec Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Panacea Biotec Ltd.
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
After receiving a response from Panacea Biotec in March 2020 over Form 483 observations stemming from a February inspection, the FDA has gone ahead and issued a warning letter to the company relating to its manufacturing facility based in Himachal Pradesh, India, citing two key cGMP violations.
The deal would include an option for expansion to 160 million doses of the mRNA-based vaccine.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- OTC, Consumer